Axonal Transport Dysfunction Validation in Parkinson's Disease

V2, Crosslink

🧫

Axonal Transport Dysfunction Validation in Parkinson's Disease

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-axonal-t

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Axonal Transport Dysfunction Validation in Parkinson's Disease ## Background and Rationale Axonal transport dysfunction represents a potentially critical upstream mechanism in Parkinson's disease (PD) pathogenesis, preceding the classical motor symptoms and dopaminergic cell loss. This clinical validation study seeks to establish axonal transport dysfunction as an early biomarker and therapeutic target by examining multiple complementary readouts in PD patients across disease stages. The exper

METHODOLOGY NOTES

**Study Design and Participant Recruitment** This prospective longitudinal clinical validation study enrolls 200 Parkinson's Disease patients (100 early-stage: Hoehn-Yahr stages 1-2; 100 mid-stage: stages 2.5-3) and 100 age-matched healthy controls (HC) stratified by age decade (50-60, 60-70, 70-80 years). PD diagnosis follows Movement Disorder Society criteria with confirmed dopaminergic deficit on DAT-SPECT imaging. Exclusion criteria include secondary parkinsonism, prior neurosurgical intervention, MRI contraindications, or significant cerebrovascular disease. Participants undergo baseline assessments including Unified Parkinson's Disease Rating Scale (UPDRS), Montreal Cognitive Assessment, and comprehensive medication inventories with washout protocols for dopaminergic agents (12-hour minimum) before testing. **Advanced Neuroimaging Protocol** High-field 3T MRI with echo-planar diffusion imaging acquires 64-direction diffusion-weighted sequences (b=1000, 2000, 3000 s/mm²) with 2mm

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.896967Z'}
summary	# Axonal Transport Dysfunction Validation in Parkinson's Disease ## Background and Rationale Axonal transport dysfunction represents a potentially critical upstream mechanism in Parkinson's disease (P
entities	{'genes': ['GAP43/HNRNPA2B1/MAP6'], 'diseases': ["Parkinson's Disease"]}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	Quantification of axonal transport dysfunction severity using DTI-derived metrics and CSF neurofilament levels, demonstrating significant correlation with disease progression rates over 24-month follo
methodology_notes	Study Design and Participant Recruitment This prospective longitudinal clinical validation study enrolls 200 Parkinson's Disease patients (100 early-stage: Hoehn-Yahr stages 1-2; 100 mid-stage: st
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.896974', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

776

Outgoing

658

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Axonal Transport Dysfunction Validation in Parkinson's Disease

derives from (16)

supports (5)

💬 Discussion